Navigation Links
Bruce Palsulich Joins Relsys International as Chief Innovation & Strategy Officer
Date:6/23/2008

IRVINE, Calif., June 23 /PRNewswire/ -- Relsys International, the leading provider of drug safety, pharmacovigilance and risk management solutions for the pharmaceutical industry, announces that Mr. Bruce Palsulich has joined the company as Chief Innovation & Strategy Officer, reporting directly to the CEO. In this role, he will oversee Relsys' future product development and direction, and drive corporate strategic initiatives.

Mr. Palsulich is one of Relsys' original employees, having been with the company since inception. He was formerly Vice President of Product Development at Relsys, departing in 2004 to pursue personal entrepreneurial initiatives. At the time, he was responsible for customer requirements, product direction and business development. Mr. Palsulich is also the original developer of the Argus Safety(TM) suite. He brings with him extensive knowledge and understanding of the pharmaceutical industry, particularly in risk management.

Mr. Dave Bajaj, President & CEO of Relsys, commented, "We welcome Bruce back to the Relsys organization. His return has been very well received by clients who have worked with him in the past. His broad, in-depth understanding of and exposure to global pharmacovigilance business practices will provide the backbone of our future product direction." Mr. Palsulich added, "Relsys has demonstrated unparalleled growth, rapidly gaining the largest user base of any drug safety system in the world. I look forward to working closely with this large client pool to continue to expand Relsys' risk management leadership."

About Relsys International

Relsys International provides the industry-leading Argus suite, a complete systems solution for drug safety, pharmacovigilance and risk management that helps pharmaceutical, biotech and medical device companies improve drug safety and ensure ongoing compliance with global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients' corporate risk management strategies. Argus Safety(TM), the company's flagship product, is the world's best selling drug safety and adverse event reporting software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit http://www.relsys.net, or call +1 949-453-1715.


'/>"/>
SOURCE Relsys International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement by Bruce Bodaken, Chairman & CEO, Blue Shield of California
2. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
3. Dr. Lewis Drusin receives American College of Physicians James D. Bruce Memorial Award
4. Statement by Bruce Bodaken on Senate Health Committee Action
5. Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
6. A product for the detection and characterization of brucellosis launched at University of Navarra
7. Richard Greco Joins Mediware Board
8. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
9. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
10. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
11. Nick Childs Joins Grey New York as Director of Content Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing dual ... opening of the Sober College Robert Pfeifer Memorial Learning Center at its location ... was attended by an overwhelming amount of alumni, family, colleagues and friends of ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: